Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Tongyan Liu, Chencheng Han, Siwei Wang, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 706

Showing 1-25 of 706 citing articles:

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
Xiaoqi Mao, Jin Xu, Wei Wang, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 1403
Tumor microenvironment complexity and therapeutic implications at a glance
Roghayyeh Baghban, Leila Roshangar, Rana Jahanban‐Esfahlan, et al.
Cell Communication and Signaling (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 1381
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi, Xiaoli Zheng, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 852
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Alexander Bagaev, Nikita Kotlov, Krystle Nomie, et al.
Cancer Cell (2021) Vol. 39, Iss. 6, pp. 845-865.e7
Open Access | Times Cited: 829
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Fanglong Wu, Jin Yang, Junjiang Liu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 451
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 433
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin, Jelena Grahovac, Anamaria Brozović, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100715-100715
Open Access | Times Cited: 389
Immunotherapy for pancreatic cancer: A 2020 update
Dimitriοs Schizas, Nikolaos Charalampakis, Christo Kole, et al.
Cancer Treatment Reviews (2020) Vol. 86, pp. 102016-102016
Closed Access | Times Cited: 360
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer
Vikrant Kumar, Kalpana Ramnarayanan, Raghav Sundar, et al.
Cancer Discovery (2021) Vol. 12, Iss. 3, pp. 670-691
Open Access | Times Cited: 324
Targeting TGFβ signal transduction for cancer therapy
Sijia Liu, Jiang Ren, Peter ten Dijke
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 264
Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance
Phillip M. Galbo, Xingxing Zang, Deyou Zheng
Clinical Cancer Research (2021) Vol. 27, Iss. 9, pp. 2636-2647
Open Access | Times Cited: 239
Epigenetic heterogeneity in cancer
Mingzhou Guo, Yaojun Peng, Aiai Gao, et al.
Biomarker Research (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 231
Cancer-associated fibroblasts: overview, progress, challenges, and directions
Qinrong Ping, Ruping Yan, Xin Cheng, et al.
Cancer Gene Therapy (2021) Vol. 28, Iss. 9, pp. 984-999
Open Access | Times Cited: 230
Biomarkers for cancer-associated fibroblasts
Chencheng Han, Tongyan Liu, Rong Yin
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 220
Single-Cell Transcriptomic Analysis of Tumor-Derived Fibroblasts and Normal Tissue-Resident Fibroblasts Reveals Fibroblast Heterogeneity in Breast Cancer
Aimy Sebastian, Nicholas R. Hum, Kelly A. Martin, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1307-1307
Open Access | Times Cited: 215
Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Aadhya Tiwari, Rakesh Trivedi, Shiaw‐Yih Lin
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 208
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Rana Mhaidly, Fatima Mechta‐Grigoriou
Seminars in Immunology (2020) Vol. 48, pp. 101417-101417
Open Access | Times Cited: 205
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 198
TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering
Jin Ma, Gonzalo Sánchez‐Duffhues, Marie‐José Goumans, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 186
Gene Therapy in Cancer Treatment: Why Go Nano?
Catarina Roma‐Rodrigues, Lorenzo Rivas-García, Pedro V. Baptista, et al.
Pharmaceutics (2020) Vol. 12, Iss. 3, pp. 233-233
Open Access | Times Cited: 177
The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis
Paris Jabeen Asif, Ciro Longobardi, Michael Hahne, et al.
Cancers (2021) Vol. 13, Iss. 18, pp. 4720-4720
Open Access | Times Cited: 174
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 174
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Hao Zhang, Lin Liu, Jinbo Liu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 170
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Mingming Zhang, Shan Gao, Dongjuan Yang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 11, Iss. 8, pp. 2265-2285
Open Access | Times Cited: 168
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
Madelon M.E. de Jong, Zoltán Kellermayer, Natalie Papazian, et al.
Nature Immunology (2021) Vol. 22, Iss. 6, pp. 769-780
Closed Access | Times Cited: 164
Page 1 - Next Page

Scroll to top